Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) ... and 300mg oral tablets, indicated for use in the ... Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 ... Arthur S. Przybyl , President and Chief Executive Officer ... our fourth product from the portfolio of approved generic ...
(Date:3/31/2015)...  Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company ... today Oxis CEO Tony Cataldo has requested ... on the Euronext exchange. Oxis shares will continue to ... Oxis Chairman and CEO Tony Cataldo ... its strategies launched in 2014 and 2015, we must ...
(Date:3/31/2015)... DUBLIN , Mar. 27, 2015 Research ... announced the addition of the "North American ... Laboratory Information System), by Type (Clinical Pathology Laboratory ... Forecast to 2019" report to their offering. ... market is estimated to grow at a CAGR ...
Breaking Medicine Technology:ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2North American Laboratory Information System (Clinical Pathology Laboratory Information System, Anatomic Pathology Laboratory Information) Market 2015-2019 2North American Laboratory Information System (Clinical Pathology Laboratory Information System, Anatomic Pathology Laboratory Information) Market 2015-2019 3
... Data,presented at the 2007 Annual Scientific Meeting of ... alli(R) (orlistat 60mg), the,only FDA- approved, over-the-counter (OTC) ... in helping them lose weight, and,not to potential ... data show that the weight loss achieved with ...
... Sanofi-aventis announced today,that the Japanese Ministry of ... for a Supplemental New Drug Application (sNDA) ... angina pectoris, non-ST elevation,myocardial infarction) for which ... Plavix(R) (clopidogrel). Approximately 100,000 patients develop ...
Cached Medicine Technology:Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 2Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5
(Date:3/31/2015)... 31, 2015 OnChip Devices , a ... wire-bondable silicon ESD diode chip targeted towards low voltage LED ... these Zeners are ideal for protecting circuits by suppressing voltage ... can handle pulses of up to 350W and 20A, providing ... IEC 61000-4-2 standard. These diodes do not exhibit any ...
(Date:3/31/2015)... Los Angeles, CA (PRWEB) March 31, 2015 ... titled “Would You Go Down the Silicone Slope?” provides a ... , dermal filler , and laser treatments . ... an example) and reality TV stars such as Kim Kardashian ... and other social media are increasingly seen as significant influences ...
(Date:3/31/2015)... 31, 2015 Clinovo, a leading ... Membership Program , the premiere voice of Northern ... life science companies. , BayBio brings together ... most innovative and productive life science cluster, helping ... of humanity’s most pressing challenges. , “We ...
(Date:3/31/2015)... March 31, 2015 Dr. St. Ledger recently ... for Advanced Dental Education. Here, he participated in the ... to create a greater predictability in cases of severely worn ... of tooth wear, and the correlation to GERD and Sleep ... Mentor at Spear Education. After the workshop he attended, ...
(Date:3/31/2015)... At Summit Breast Care, their passion is to provide ... caring manner. , Summit Breast Care has achieved national recognition ... cancer. They treat thousands of patients annually, not just ... Their doctors continue to be recognized as ‘Top Doctors’ ... Breast Care were planted in the mind and spirit of ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Cosmetic Surgery: Does Social Media Pressure Young Girls to Get Botox and Fillers? 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The dentists at Upper Montclair Dental Associates are happy to announce exciting new happenings at their practice. 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... and Eliza Hall Institute (WEHI) has contributed significantly ... biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, ... Licensing Agreement, Merck Serono will seek to develop ... autoimmune conditions. These prospective treatments will be based ...
... July 2 SuperGen, Inc.,(Nasdaq: SUPG ), ... and commercialization of therapies for solid tumors and,hematological ... and Chief Executive Officer, is scheduled to present ... 9, 2008 at the,Mandarin Oriental Hotel in New ...
... 2 The Female Health Company,(Amex: FHC ) ... Russell,Microcap(R) Index after the Russell Investment Group reconstituted its,comprehensive ... 27, 2008., The Russell Microcap(R) Index measures the ... the U.S. equity market. The Russell,Microcap(R) Index includes the ...
... Calif. and YOKOHAMA CITY, Japan, July 2 ... technology company,and Tokyo Electron Device Limited (TED), ... of inrevium evaluation board solutions, and,provider of ... the,distribution of Samplify,s patented Prism(TM) signal compression ...
... improved version of AmWay's MagnaBloc. , ... Memphis, TN ... pain management, is now available in a new, stronger form: ... released in the United States, and will be available worldwide within ...
Cached Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:MS drug development agreement based on WEHI's medicinal chemistry 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:The Female Health Company Added to Russell Microcap(R) Index 2Health News:The Female Health Company Added to Russell Microcap(R) Index 3Health News:The Female Health Company Added to Russell Microcap(R) Index 4Health News:Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology 2Health News:New MagnaBloc™ Product Available from Gradient Medical 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: